Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539055 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT03539055 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants.
The verdict
NCT03539055, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.) to prevent device related thrombus.
Interventions
- DRUG Dabigatran Etexilate Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539055
The ClinicalTrials.gov registry entry for NCT03539055 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dabigatran Etexilate Oral Capsule is the first listed.
NCT03539055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03539055 about?
NCT03539055 is a clinical study titled "Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).". Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post impla...
What is the current status of trial NCT03539055?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2018-09-01. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT03539055?
The interventions under investigation include: Dabigatran Etexilate Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT03539055?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.